Creating a Holistic Extractables and Leachables (E&L) Program for Biotechnology Products

References

1. 1.↵
   ICH. Q8(R2). Pharmaceutical Development. 2009.
2. 2.↵
   ICH. Q9. Quality Risk Management. 2005.
3. 3.↵
   ICH, Q3A(R2). Impurities in New Drug Substances. 2006.
4. 4.↵
   ICH. Q3B(R2). Impurities in New Drug Products. 2006.
5. 5.↵
   ICH. Q3C(R5). Impurities: Guideline for Residual Solvents. 2011.
6. 6.↵
   ICH. Consensus Guideline M7. Assessment and Control of DNA Reactive (Mutagenic) Impurities in Pharmaceuticals to Limit Potential Carcinogenic Risk. 2014.
7. 7.↵
   ICH. Q3D. Guideline for Elemental Impurities. 2014.
8. 8.↵
   1. Ball D.,
   2. Blanchard J.,
   3. Jacobson-Kram D.,
   4. McCellan R. O.,
   5. McGovern T.,
   6. Norwood D. L.,
   7. Vogel W. M.,
   8. Wolff R.,
   9. Nagao L.

   Development of safety qualification thresholds and their use in orally inhaled and nasal drug product evaluation. Toxicol. Sci. 2007, 97 (2), 226–236.

   OpenUrlAbstract/FREE Full Text
9. 9.↵
   PQRI. Safety thresholds and best practices for extractables and leachables in orally inhaled and nasal drug products. Bethsda, MD. September 8, 2006.
10. 10.↵
    PQRI. Establishing Threshold Levels of Extractables & Leachables in Parenteral & Opthalmic Drug Products. Discussion of the Proposed PQRI Qualification Plan. USP/PQRI Workshop (Make-up Session) presented by Doug Ball, Rockville, MD. April 28, 2014.
11. 11.↵
    1. Paskiet D.,
    2. Jenke D.,
    3. Ball D.,
    4. Houston C.,
    5. Norwood D. L.,
    6. Markovic I.

    The Product Quality Research Institute (PQRI) Leachables and Extractables Working Group Initiatives for Parenteral and Ophthalmic Drug Product (PODP). PDA J. Pharm. Sci. Technol. 2013, 67 (5), 430–447.

    OpenUrlAbstract/FREE Full Text
12. 12.↵
    1. Markovic I

    . Regulatory Perspective on Extractables & Leachables in Biologics: Quality Considerations. USP/PQRI Workshop (Make-up Session), Rockville, MD. April 28, 2014.
13. 13.↵
    IdeaConsult Ltd. Toxtree (Estimation of Toxic Hazard—A Decision Tree Approach) v.2.6.6. http://toxtree.sourceforge.net/.
14. 14.↵
    EMEA. Guideline on the Limits of Genotoxic Impurities. CPMP/SWP/5199/02. EMEA/CHMP/QWP/251344/2006. 2006.
15. 15.↵
    1. Benigni R.,
    2. Bossa C.

    Structure alerts for carcinogenicity and the Salmonella assay system: a novel insight through the chemical relational databases technology. Mutat. Res. 2008, 659 (3), 248–261.

    OpenUrlCrossRefPubMedWeb of Science
16. 16.↵
    1. Cramer G. M.,
    2. Ford R. A.,
    3. Hall R. L.

    Estimation of toxic hazard - a decision tree approach. Food Cosmet. Toxicol. 1978, 16 (3), 255–276.

    OpenUrlCrossRefPubMedWeb of Science
17. 17.↵
    FDA. CFSAN. Threshold of Toxicological Concern. A Historical Perspective. Presentation by Mitchell Cheeseman at Society of Toxicology Annual Conference. 2011.
18. 18.↵
    1. Kroes R.,
    2. Renwick A. G.,
    3. Cheeseman M.,
    4. Kleiner J.,
    5. Mangelsdorf I.,
    6. Piersma A.,
    7. Schilter B.,
    8. Schlatter J.,
    9. van Schothorst F.,
    10. Vos J. G.,
    11. Wourtzen G.

    Structure-based thresholds of toxicological concern (TTC): guidance for application to substances present at low levels in the diet. Food Chem. Toxicol. 2004, 42 (1), 65–83.

    OpenUrlCrossRefPubMedWeb of Science
19. 19.↵
    1. Patlewicz G.,
    2. Jeliazkova N.,
    3. Safford R. J.,
    4. Worth A. P.,
    5. Aleksiev B.

    An evaluation of the implementation of the Cramer classification scheme in the Toxtree software. SAR QSAR Environ. Res. 2008, 19 (5–6), 495–524.

    OpenUrlPubMed
20. 20.↵
    EMEA. Guideline on the specification limits for residues of metal catalysts or metal reagents. Document Reference EMEA/CHMP/SWP/4446/2000. 2008.
21. 21.↵
    IOM. Dietary Reference Intakes. The Essential Guide to Nutrient Requirements. The National Academies Press: Washington, D.C. 2006.
22. 22.↵
    1. Jiang Y.,
    2. Nashed-Samuel N.,
    3. Li C.,
    4. Liu W.,
    5. Pollastrini J.,
    6. Mallard D.,
    7. Wen Z.-Q.,
    8. Fujimori K.,
    9. Pallitto M.,
    10. Donahue L.,
    11. Chu G.,
    12. Torraca G.,
    13. Vance A.,
    14. Mire-Sluis A.,
    15. Freund E.,
    16. Davis J.,
    17. Narhi L.

    Tungsten-induced protein aggregation: solution behavior. J. Pharm. Sci. 2009, 98 (12), 4695–4710.

    OpenUrlCrossRefPubMed
23. 23.↵
    1. Liu W.,
    2. Swift R.,
    3. Torraca G.,
    4. Nashed-Samuel Y.,
    5. Wen Z.-Q.,
    6. Jiang Y.,
    7. Vance A.,
    8. Mire-Sluis A.,
    9. Freund E.,
    10. Davis J.,
    11. Narhi L.

    Root cause analysis of tungsten-induced protein aggregation in pre-filled syringes. PDA J. Pharm. Sci. Technol. 2010, 64 (1), 11–19.

    OpenUrlAbstract/FREE Full Text
24. 24.↵
    1. Aptula A. O.,
    2. Roberts D. W.

    Mechanistic applicability domains for nonanimal-based prediction of toxicological end points: general principles and application to reactive toxicity. Chem. Res. Toxicol. 2006, 19(8), 1097–1105.

    OpenUrlCrossRefPubMedWeb of Science
25. 25.↵
    1. Enoch S. J.,
    2. Madden J. C.,
    3. Cronin M. T.

    Identification of mechanisms of toxic action for skin sensitisation using a SMARTS pattern based approach. SAR QSAR Environ. Res. 2008, 19(5–6), 555–578.

    OpenUrlCrossRefPubMed
26. 26.↵
    1. Enoch S. J.,
    2. Ellison C. M.,
    3. Schultz T. W.,
    4. Cronin M. T.

    A review of the electrophilic reaction chemistry involved in covalent protein binding relevant to toxicity. Crit. Rev. Toxicol. 2011, 41 (9), 783–802.

    OpenUrlCrossRefPubMed
27. 27.↵
    1. Schultz T. W.,
    2. Yarbrough J. W.,
    3. Hunter R. S.,
    4. Aptula A. O.

    Verification of the structural alerts for Michael acceptors. Chem. Res. Toxicol. 2007, 20(9), 1359–1363.

    OpenUrlPubMed
28. 28.↵
    1. Markovic I.

    Regualtory and Scientific Perspectives on Extractables and Leachables. Sartorius Stedim biotech Extractables & Leachables Forum, Boston, MA. September 19–20, 2012.
29. 29.↵
    1. Markovic I

    . Considerations for Extractables and Leachables in Single Use Systems: A Risk-Based Perspective. Presentation at PDA Single Use Systems Workshop, Bethesda, MD. June 22–23, 2011.
30. 30.↵
    1. Allen N. S.,
    2. Edge M.

    Fundamentals of Polymer Degradation and Stabilisation. Elsevier Science Publishers Ltd.: Essex, England, 1992.
31. 31.↵
    1. Jenke D. R.,
    2. Stults C. L. M.,
    3. Paskiet D. M.,
    4. Ball D. J.,
    5. Nagao L. M.

    Materials in manufacturing and packaging systems as sources of elemental impurities in packaged drug products: aliterature review. PDA J. Pharm. Sci. Technol. 2015, 69(1), 1–48.

    OpenUrlAbstract/FREE Full Text
32. 32.↵
    1. Hammond K.,
    2. Shatkina J.,
    3. Leaderer B. P.

    Determination of the mass extractable in organic solvents by evaporative light-scattering detection. Appl. Occup. Environ. Hyg. 1992, 7 (1), 49–54.

    OpenUrl
33. 33.↵
    1. Jenke D.,
    2. Couch T. R.,
    3. Robinson S. J.,
    4. Volz T. J.,
    5. Colton R. H.

    The use of TOC reconciliation as a means of establishing the degree to which chromatographic screening of plastic material extracts for organic extractables is complete. PDA J. Pharm. Sci. Technol. 2014, 68 (3), 256–270.

    OpenUrlAbstract/FREE Full Text
34. 34.↵
    1. Nashed-Samuel N.,
    2. Liu D.,
    3. Fujimori K.,
    4. Perez L.,
    5. Lee H.

    Extractable and leachable implication of biological products in prefilled syringes. Am. Pharm. Rev. 2011, Jan/Feb, 74–80.
35. 35.↵
    1. Brockmann W.,
    2. Geiβ P. L.,
    3. Klinger J. K.,
    4. Schroder B.,
    5. Mikhail B.

    Adhesive Bonding: Adhesives, Applications and Processess; Wiley-VCH Verlag GmbH & Co. KGaA: Weinheim, Germany 2009.
36. 36.↵
    1. Stavitskaya L.,
    2. Minnier B. L.,
    3. Kruhlak N. L.

    Benchmarking Assessment of Open Source and Newly Released Salmonella Mutagenicity (Q)SAR Models for Potential Use Under ICH M7. Abstract # 2273B. Society of Toxicology Annual Conference, Phoenix, AZ, March 22–27, 2014.
37. 37.↵
    1. Kruhlak N. L.

    FDA/CDER Current Practices for (Q)SAR Analysis Under ICH M7. Presentation at webinar sponsored by Lhasa, Ltd., 2014.
38. 38.↵
    FDA. Guidance for Industry. Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers. 2005.
39. 39.↵
    1. Jenke D.,
    2. Carlson T.

    A compilation of safety impact information for extractables associated with materials used in pharmaceutical packaging, delivery, administration, and manufacturing systems. PDA J. Pharm. Sci. Technol. 2014, 68 (5), 407–455.

    OpenUrlAbstract/FREE Full Text
40. 40.↵
    1. Klaassen C. D.

    1. Gregus Z.

    Mechanisms of Toxicity. In Casarett and Doull's Toxicology. The Basic Science of Poisons, 8th ed.; Klaassen C. D., Ed.; McGraw-Hill Education: New York, 2013.
41. 41.↵
    1. Jenke D.

    The Early Development Stage. In Compatibility of Pharmaceutical Products and Contact Materials. Safety Considerations Associated with Extractables and Leachables; John Wiley & Sons, Inc.: Hoboken, NJ, 2009; pp 191–228.
42. 42.↵
    1. Zhang Z.,
    2. Shah B.,
    3. Bondarenko P. V.

    G/U and certain wobble position mismatches as possible main causes of amino acid misincorporations. Biochemistry 2013, 52(45), 8165–8176.

    OpenUrlCrossRefPubMedWeb of Science
43. 43.↵
    1. Wong S. S.

    Chemistry of Protein conjugation and Cross-linking; CRC Press: Boca Raton, FL, 1993.
44. 44.↵
    1. Liu D.,
    2. Nashed-Samuel N.,
    3. Bondarenko P. V.,
    4. Brems D. N.,
    5. Ren D.

    Interactions between therapeutic proteins and acrylic acid leachable. PDA J. Pharm. Sci. Technol. 2012, 66 (1), 12–19.

    OpenUrlAbstract/FREE Full Text
45. 45.↵
    1. Hovorka S. W.,
    2. Schöeneich C.

    Oxidative degradation of pharmaceuticals: theory, mechanisms and inhibition. J. Pharm. Sci. 2001, 90(3), 253–269.

    OpenUrlCrossRefPubMed
46. 46.↵
    1. Manning M. C.,
    2. Chou D. K.,
    3. Murphy B. M.,
    4. Payne R. W.,
    5. Katayama D. S.

    Stability of protein pharmaceuticals. An update. Pharm. Res. 2010, 27 (4), 544–575.

    OpenUrlCrossRefPubMed
47. 47.↵
    1. Luo Q.,
    2. Joubert M. K.,
    3. Stevenson R.,
    4. Ketchem R. R.,
    5. Narhi L. O.,
    6. Wypych J.

    Chemical modifications in therapeutic protein aggregates generated under different stress conditions. J. Biol. Chem. 2011, 286 (28), 25134–25144.

    OpenUrlAbstract/FREE Full Text
48. 48.↵
    1. Lam X. M.,
    2. Lai W. G.,
    3. Chan E. K.,
    4. Ling V.,
    5. Hsu C. C.

    Site-specific tryptophan oxidation induced by autocatalytic reaction of polysorbate 20 in protein formulations. Pharm. Res. 2011, 28 (10), 2543–2555.

    OpenUrlPubMed
49. 49.↵
    1. Otzen D

    . Protein–surfactant inteactions. A tale of many states. Biochimic. Biophys. Acta 2011, 1814(5), 562–591.

    OpenUrl
50. 50.↵
    1. Kishore R. S.,
    2. Kiese S.,
    3. Fischer S.,
    4. Pappenberger A.,
    5. Grauschopf U.,
    6. Mahler H. C.

    The degradation of polysorbates 20 and 80 and its potential impact on the stability of biotherapeutics. Pharm. Res. 2011, 28 (5), 1194–1210.

    OpenUrlPubMed
51. 51.↵
    1. Singh S. K.

    Impact of product-related factors on immunogenicity of biotherapeutics. J. Pharm. Sci. 2010, 100(2), 354–387.

    OpenUrlPubMed
52. 52.↵
    1. Meyer B. K.,
    2. Ni A.,
    3. Hu B.,
    4. Shi L.

    Antimicrobial preservative use in parenteral products past and present. J. Pharm. Sci. 2007, 96 (12), 3155–3167.

    OpenUrlCrossRefPubMed
53. 53.↵
    1. Seidl A.,
    2. Hainzl O.,
    3. Richter M.,
    4. Fischer R.,
    5. Bohm S.,
    6. Deutel B.,
    7. Hartinger M.,
    8. Windisch J.,
    9. Casadevall N.,
    10. London G. M.,
    11. Macdougall I.

    Tungsten-induced aggregation of epoetin alfa as a cause of immunogenicity. Pharm. Res. 2012, 29 (6), 1454–1467.

    OpenUrlCrossRefPubMed
54. 54.
    General Injectables & Vaccine Inc. Package Insert for Bacteriostatic Water–Water Injection, Solution. 2004.
55. 55.
    1. Yamamoto K.,
    2. Tajima K.,
    3. Mizutani T.

    The acute toxicity of butylated hydroxytoluene and its metabolites in mice. Toxicol. Lett. 1980, 6(3), 173–175.

    OpenUrlCrossRefPubMed
56. 56.
    JECFA. WHO Food Additive Series 32. 2-Ethyl-1-hexanol. 1993.
57. 57.
    EPA. IRIS Integrated Risk Information System. Caprolactam. http://www.expub.com (accessed December 30, 2011).
58. 58.
    OECD. SIDS Initial Assessment Report. Maleic Acid, Dibutylester. CASRN# 105-76-0. 1998.
59. 59.
    EPA. IRIS Integrated Risk Information System. Xylenes. CASRN 1330-20-7. http://www.expub.com (accessed January 10, 2013).
60. 60.
    EPA. Provisional Peer-Reviewed Toxicity Values for 4-Methylphenol (p-Cresol) (CASRN 106-44-5). 2010.
61. 61.
    OECD. SIDS Initial Assessment Report. Hexylene Glycol, CASRN# 107-41-75. 2001.
62. 62.
    1. Johnson W. J.,
    2. Bergfeld W. F.,
    3. Belsito D. V.,
    4. Hill R. A.,
    5. Klaassen C. D.,
    6. Liebler D. C.,
    7. Marks J. G. J.,
    8. Shank R. C.,
    9. Slaga T. J.,
    10. Snyder P. W.,
    11. Andersen F. A.

    Safety assessment of cyclomethicone, cyclotetrasiloxane, cyclopentasiloxane, cyclohexasiloxane and cycloheptasiloxane. Int. J. Toxicol.2011, 30 (Suppl. 3), 149S–227S.

    OpenUrlAbstract/FREE Full Text
63. 63.
    EPA. IRIS Integrated Risk Information System. Toluene. http://www.expub.com (accessed June 26, 2012).
64. 64.
    OECD, eChemPortal. n.d.
65. 65.
    EPA. Integrated Risk Information System. Ethylene glycol; CASRN 107-21-1. 1989.
66. 66.
    EU. Scientific Committee for Food (SCF). Reports for the Scientific Committee for Food. Seventh series. Report EUR 10788. 1986.
67. 67.
    EPA, SIDS. n-Undecane. 2010.
68. 68.
    EPA. Toxicology Review of Ethylene Glycol Monobutyl Ether (EGBE) (CAS No. 111-76-2). In support of Summary Information on the Integrated Risk Information System (IRIS). EPA-635/R-08/006F. 2010.
69. 69.
    European Chemicals Bureau. European Union Risk Assessment Report. 2-(2-Methoxyethoxy)ethanol. CAS No. 111-77-3. 1999.
70. 70.
    EPA. Provisional Peer-reviewed Toxicity Values for Diethylene Glycol Monoethyl Ether (DGEE). CASRN 111-90-0. 2009.
71. 71.
    1. Fleischman R. W.,
    2. Baker J. R.,
    3. Hagopian M.,
    4. Wade G. G.,
    5. Hayden D. W.,
    6. Smith E. R.,
    7. Weisburger J. H.,
    8. Weisburger E. K.

    Carcinogenesis bioassay of acetamide, hexanamide, adipamide, urea and P-tolylurea in mice and rats. J. Environ. Pathol. Toxicol. 1980, 3 (5–6), 149–170.

    OpenUrlPubMedWeb of Science
72. 72.
    EPA, Provisional Peer-reviewed Toxicity Values for Diethylene Glycol Monobutyl Ether (DGBE). CASRN 112-34-5). 2009.
73. 73.
    ECHA Eicosane (CAS 112-95-8). http://www.expub.com (accessed October 7, 2014).
74. 74.
    OECD, SIDS Initial Assessment Report (DRAFT). Diethylene Glycol Ethers Category. 2005.
75. 75.
    OECD, SIDS. 1-Dodecanol. CAS No. 112-53-8. UNEP Publications. 2000.
76. 76.
    ACC Index of Robust Summaries. ACC FND Amides Chemical Category. http://www.expub.com (accessed June 19, 2013).
77. 77.
    BIBRA. Toxicity profile—erucamide, 2nd ed.; BIBRA Information Services Ltd., 2001.
78. 78.
    OECD, SIDS. Higher Olefins—Category: Hexene CAS No. 25264-93-1; Heptene CAS No. 25339-56-4; Octene CAS No. 25377-83-7; Nonene CAS No. 27215-95-8; Decene CAS No. 25339-53-1; Dodecene CAS No. 25378-22-7; Alkenes C10–13 CAS No. 85535-87-1; 1-Hexadecene CAS No. 629-73-2; 1-Octadecene CAS No. 112-88-9. UNEP Publications. 2004.
79. 79.
    European Commission, European Union Risk Assessment Report. Tris (2-chloroethyl) Phosphate. TCEP. 2009.
80. 80.
    OECD. SIDS Initial Assessment REport. 6,6′-Di-tert-butyl-2,2'-methyleneki-p-cresol. CASRN # 119-47-1. 2000.
81. 81.
    1. Thomas J. O.,
    2. Ribelin W. E.,
    3. Woodward J. R.,
    4. Deeds F.

    The chronic toxicity of diphenylamine for dogs. Toxicol. Appl. Pharmacol. 1967, 11(1), 184–194.

    OpenUrlPubMed
82. 82.
    JECFA. Butylated hydroxytoluene: Toxicological evaluation of certain food additives and contaminants (WHO Food Additives Series 35). http://www.expub.com (accessed February 11, 2015).
83. 83.
    JECFA. Butylated hydroxytoluene (BHT): Safety evaluation of certain food additives (WHO Food Additives Series 42). http://www.expub.com (accessed February 11, 2015).
84. 84.
    ECHA. CAS no. 13048-33-4. 2012.
85. 85.
    EPA. Provisional Peer-Reviewed Toxicity Values for Dimethyl phthalate (CASRN 131-11-3). 2007.
86. 86.
    NICNAS. Millad 3988. National Industrial Chemicals Notification and Assessment Scheme (NICNAS). File No. NA/179. 1994.
87. 87.
    ECHA REACH Registered Compounds. CAS No. 13586-56-2.
88. 88.
    HSDB^® Castor oil. CAS no. 8001-79-4. http://www.expub.com (accessed July 30, 2013).
89. 89.
    1. Singh A. R.,
    2. Lawrence W. H.,
    3. Autian J.

    Embryonic–fetal toxicity and teratogenic effects of adipic acid esters in rats. J. Pharm. Sci.1973, 62 (10), 1596–1600.

    OpenUrlPubMed
90. 90.
    Dow Corning, A 28-day subchronic oral gavage feasibility study of various low molecular weight silicone oligomers in rats. OTS0590105.1990.
91. 91.
    OECD. SIDS Initial Assessment Report for SIAM 14. 2,6-Di-tert-butyl-p-cresol (BHT). CAS no. 128-37-0.
92. 92.
    OECD, SIDS Initial Assessment Report. High Boiling Ethylene Glycol Ethers Category: Triethylene glycol butyl ether, CAS No. 143-22-6; Tetraethylene glycol methyl ether, CAS No: 23783-42-8; Tetraethylene glycol butyl ether, CAS No. 1559-34-8. 2002.
93. 93.
    JECFA. WHO Food Additive Series 44. Sweetening Agent: Erythritol. 2000.
94. 94.
    1. Bingham E.,
    2. Cohrssen B.,
    3. Powell C. H.

    , Patty's Toxicology 2001; Vol. 5.
95. 95.
    RTECS^®, Benzaldehyde, 3,5-di-tert-butyl-4-hydroxy-. CAS No. 1620-98-0. 2011.
96. 96.
    European Chemicals Bureau, IUCLID Dataset. Triphenylphosphine oxide. CAS 1733-57-9. 2000.
97. 97.
    EC. European Chemicals Bureau. Octabenzone. CAS 1843-05-6. IUCLID Dataset. 2000.
98. 98.
    EPA. High Production Volume (HPV) Chemical Challenge Program. Data Summary & Test Plan. for 2-Hydroxy-4-n-octoxybenzophenone. CAS 1843-05-6 2001.
99. 99.
    EPA. Screening-level hazard characterization for 2-hydroxy-4-n-octoxybenzophenone (CASRN 1843-05-6). 2010.
100. 100.
     EPA. Atrazine: Finalization of Interim Reregistration Eligibility Decision and Completion of Tolerance REassessment and Reregistration Eligibility Process. 2006.
101. 101.
     EPA. TSCATS Abstract summary on a repeated dose study submitted by Ciba-Geigy Corporation on metilox acid (20170-32-5). http://www.exppub.com (accessed October 1, 2012).
102. 102.
     OECD SIDS Initial Assessment Report for SIAM 22. Octadecyl 3-(3,5-di-tert-butyl-4-hydroxyphenyl)propionate. CAS 2082-79-3. http://www.Expub.com (accessed February 18, 2014).
103. 103.
     Alfa Aesar. Ethyl 4-ethoxybenzoate (CAS 23676-09-7). Material Safety Data Sheet. 2009.
104. 104.
     EPA. 2,6-Diisopropylnaphthalene (PC Code 055803). Biopesticide Registration Document. http://www.expub.com (accessed February 18, 2014).
105. 105.
     1. Bingham E.,
     2. Cohrssen B.

     1. Cavender F. L.,
     2. Glycols

     . In Patty's Toxicology, 6th [electronic] ed.; Bingham E., Cohrssen B., Eds.; John Wiley & Sons, Inc.: Hoboken, NJ, 2012; Vol. 4.
106. 106.
     JECFA Summary of Evaluations Performed by the Joint FAO/WHO Expert Committee on Food Additives. Polyethylene glycols. http://www.expub.com (accessed August 27, 2012).
107. 107.
     OECD. SIDS Initial Assessment Profile. Alfa Olefin Category. SIAM 11. 23-26 January 2001. 2001.
108. 108.
     OECD, SIDS. Pentaethylene Glycol. CAS No. 4792-15-8. 2007.
109. 109.
     EPA. Supporting Documents for Initial Risk-based Prioritization of High Production Volume Chemicals. 1,3,5-Trioxane. CASRN 110-88-3. 2008.
110. 110.
     European Chemicals Bureau, IUCLID Dataset. Substance ID: 31570-04-0. 2000.
111. 111.
     EPA. SIDS Initial Assessment Report for SIAM. Long Chain Alcohols. 2006.
112. 112.
     1. Burns-Naas L.,
     2. Meeks R. G.,
     3. Kolesar G. B.,
     4. Mast R. W.,
     5. Elwell M. H.,
     6. Thevenaz P.

     Inhalation toxicicology of octamethylcyclotetrasiloxane (D4) following a 3-month nose-only exposure in Fischer 344 rats. Int. J. Toxicol.2002, 21 (1), 39–53.

     OpenUrlAbstract/FREE Full Text
113. 113.
     CA EPA OEHHA Poroposition 65 No Significant Risk Levels (NSRLs) for Carcinogens and Maximum Allowable Dose Levels (MADLs) for Chemicals Causing Reproductive Toxicity. August 2013. http://www.expub.com (accessed November 6, 2012).
114. 114.
     EPA. TSCA Initial submission: Ninox HCDO-Twenty-eight Day Repeated Dose Oral (Gavage) Toxicity Study in the Rat, with Cover Letter. November 20, 2000. 2000.
115. 115.
     EPA. Supporting Documents for Initial Risk-based Prioritization of High Production Volume. Chemicals—Dibasic Esters Category. 2008.
116. 116.
     OECD, SIDS Initial Assessment Report. Hexamethylene Glycol. CASRN no. 629-11-8. 2000.
117. 117.
     EPA, Integrated Risk Information System. Benzoic acid; CASRN 65-85-0. 1993.
118. 118.
     1. Komsta E.,
     2. Chu I.,
     3. Secours V. E.,
     4. Valli V. E.,
     5. Villeneuve D. C.

     Results of a short-term toxicity study for three organic chemicals found in Niagara River drinking water. Bull. Environ. Contam. Toxicol. 1988, 41(4), 515–522.

     OpenUrlPubMed
119. 119.
     ECHA Pentaerythritol tetrakis(3-(3,5-di-tert-butyl-4-hydroxyphenyl)propionate). CAS number 6683-19-8. http://www.echa.europa.eu (accessed February 20, 2014).
120. 120.
     EPA Robust summary and test plans. Irganox 1010. Tetrakis-(methylene-(3,5-di-tert)-butyl-4-hydrocinnamate))methane. CAS No. 6683-19-8. Revised summaries. http://www.expub.com (accessed January 8, 2013).
121. 121.
     1. Jonmaire P. W.,
     2. Sowinski E. J.,
     3. Gephart L. A.,
     4. Becci P. J.

     Subchronic feeding study in beagle dogs of 2,2′-oxamidobis (ethyl-3(3,5-di-tert-butyl-4-hydroxyphenyl) propionate. J. Toxicol. Environ. Health 1985, 6 (2), 277–283.

     OpenUrl
122. 122.
     1. Pham-Huu-Chanh,
     2. Azum-Gélade M. C.,
     3. Nguyen-van-Bac

     ; NguyenDat-Xuong Toxicological studies of the N-n-propyl and N-n-butyl derivatives of formamide. Toxicol. Appl. Pharmacol. 1973, 26(4), 596–605.

     OpenUrlPubMed
123. 123.
     OECD SIDS Initial Assessment Report. Triethylphosphate. CASRN# 78-40-0.
124. 124.
     EPA IRIS Isophorone. CASRN 78-59-1. http://www.expub.com (accessed November 6, 2012).
125. 125.
     EPA, Integrated Risk Information System. Acrylic acid; CASRN 79-10-7. 1994.
126. 126.
     EPA, Provisional Peer Reviewed toxicity Values for Triphenylphosphine Oxide (CASRN 791-28-6). 2007.
127. 127.
     European Chemicals Bureau, IUCLID Dataset. Methacrylic Acid. 2000.
128. 128.
     EPA, Integrated Risk Information System. Diethyl Phthalate; CASRN 84-66-2. 1993.
129. 129.
     EPA, Integrated Risk Information System. Dibutyl phthalate (CASRN 84-74-2). 1990.
130. 130.
     EPA, Integrated Risk Information System: Phthalic anhydride (CASRN 85-44-9). 1988.
131. 131.
     1. Saillenfait A. M.,
     2. Gallissot F.,
     3. Langonne I.,
     4. Sabate J. P.

     , Developmental toxicity of N-methyl-2-pyrrolidone administered orally to rats. Food Chem. Toxicol. 2002, 40, 1705-1712.

     OpenUrlCrossRefPubMedWeb of Science
132. 132.
     1. Dacre J. C.

     , Toxicologic Studies with 2,6-Di-tert-butyl-4-hydroxymethylphenol in the Rat. Toxicol. Appl. Pharmacol. 1970, 117 (3), 669-678.

     OpenUrl
133. 133.
     1. Jha A. M.,
     2. Singh A. C.,
     3. Bharti M.

     Germ Cell Mutagenicity of Phthalic Acid in Mice. Mutat. Res. 1998, 422 (2), 207–212.

     OpenUrlPubMed
134. 134.
     EPA, Integrated Risk Information System. 2-Methylphenol; CASRN 95-48-7. 1990.
135. 135.
     JECDB 2,4-Di-tert-butylphenol. http://www.expub.com (accessed October 23, 2013).
136. 136.
     FFHPVC, Flavor and Fragrance High Production Volume (FFHPVC) Cyclohexyl Derivatives Consortium. Revised Test Plan for Alky-substituted Cyclohexanol Derivatives. 2006.
137. 137.
     1. Dickson M. A.,
     2. Carvajal R. D.,
     3. Merrill A. H. J.,
     4. Gonen M.,
     5. Cane L. M.,
     6. Schwartz G. K.

     A Phase I Clinical Trial of Safingol in Combination with Cisplatin in Advanced Solid Tumors. Clin. Cancer Res. 2011, 17 (8), 2484–2492.

     OpenUrlAbstract/FREE Full Text
138. 138.
     NTP. Toxicology and Carcinogenesis Studies of 4,4′-Thiobis(6-tert-butyl-3-cresol; (CAS No. 96-69-5) in F344/n rats and B6C3F1 Mice. Technical Report Series No. 435. 1994.
139. 139.
     EPA. Hazard Characterization Document. Screening-level Hazard Characterization—Bridged Alkyl Phenol Category. 2010.